Premium
Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: A single center experience
Author(s) -
Zhang Li,
Zhao Hui,
Zhu Xiaofan,
Chen Yumei,
Zou Yao,
Chen Xiaojuan
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21510
Subject(s) - medicine , arsenic trioxide , acute promyelocytic leukemia , single center , gastroenterology , pediatrics , apoptosis , retinoic acid , biochemistry , chemistry , gene
Background There are very limited data reported about childhood acute promyelocytic leukemia (APL), especially with arsenic trioxide (As 2 O 3 ) treatment. We review the clinical course and treatment outcome of 65 children APL. Procedure Between January 1999 and December 2005, 65 children (<18 years) with newly diagnosed APL were treated. Results Three groups of patients were identified according to the different induction regimens. Forty patients were given ATRA alone (group 1, G1), 8 patients were given As 2 O 3 alone (group 2, G2), 15 patients (group 3, G3) were treated with combination of ATRA and As 2 O 3 . Two patients received cytosine arabinoside and died at days 2 and 4, respectively. The CR rate of G1 was 95% (38/40). The overall CR rate of G2+G3 was 91.3% (21/23). Toxicity of ATRA and As 2 O 3 were minimal and recoverable during induction. Five children had a hematologic relapse and two developed molecular relapse. Five of them were successfully treated with ATRA alone or combined with As 2 O 3 . The 5‐year estimate of EFS, DFS and OS between G1 and G2+G3 has no difference. Conclusion As 2 O 3 is an effective and well tolerable therapy for children with APL and it may be used in those who have dose limiting side effects of ATRA, but also for those with newly diagnosed or relapsed APL. Pediatr Blood Cancer 2008;51:210–215. © 2008 Wiley‐Liss, Inc.